Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The consumption of an adequate quantity of protein in the diet is essential to maintain a healthy body composition and functioning. It is also well established that all proteins are not equal regarding their ability to promote health benefits. Recently, we have innovated in that matter by showing that under the context of high intake of dietary fat, the dairy protein casein was more effective than a mix of proteins representative of a western diet to prevent body weight gain and insulin resistance. This was explained in part by modifications of the gut microbiota. This finding represents the main conceptual basis of the present research program that is aimed to determine the impact of dairy protein from yogurt compared to a plant-based equivalent on body composition indicators including muscle mass and bone mineral density, in relation to the profile of the gut microbiota, the production of newly discovered protein-derived metabolites, and markers of metabolic health. This program will include a human and an animal component requiring the testing of these variables before and after a standardized intervention. The human component will be a clinical study consisting of a 12-week diet-based weight loss intervention in postmenopausal overweight women being randomly assigned to one of the three following groups: yogurt, plant-based yogurt, or kept on diet without supplements. The animal experimentation will permit to causally determine the implication of the gut microbiota in the protein effects following transfer of the human bacteria to germ free mice and validate the benefits seen in humans. It is anticipated that these two complementary investigative approaches will allow a thorough documentation of the impact of fermented dairy protein on body composition and functioning, a better understanding of the underlying mechanisms, and the identification of new biomarkers to better appreciate related health benefits.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dairy yogurt | Experimental |
| |
| Plant-based yogurt | Active Comparator |
| |
| No yogurt | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dairy yogurt | Dietary Supplement | Dairy yogurt: two serving daily |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change in bone health | Assessment of bone mineral density using Dual X-ray Absorptiometry scan | At baseline and at the end of the intervention (12 weeks) |
| Change in bone health | Assessment of bone turnover biomarkers (osteocalcin, c-telopeptide, Amino terminal propeptide of type 1 procollagen) (all in ng\mL) | At baseline and at the end of the intrevention (12 weeks) |
| Change in gut microbiota | Assessment of global variation of the fecal microbiota | At baseline and at the end of the intervention (12 weeks) |
| Change in gut microbiota function | Assessment of short-chain fatty acid (SCFA) in feces | At baseline and at the end of the intervention (12 weeks) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in body weight | At baseline and at the end of the intervention (12 weeks) | |
| Change in anthropometric measures | Assessment of body mass index (BMI) using weight and height. These two measurements will be combined to calculate BMI in kg/m2 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Julie Marois, M.Sc. | Contact | 1-418-656-5258 | julie.marois@fsaa.ulaval.ca |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| INAF, Université Laval | Recruiting | Québec | Quebec | G1V 0A6 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Plant based yogurt |
| Dietary Supplement |
Plant based yogurt: two servings daily |
|
| No yogurt | Dietary Supplement | No yogurt: zero serving yogurt |
|
| At baseline and at the end of the intervention (12 weeks) |
| Change in anthropometric measure | Assessment of waist circumference | At baseline and at the end of the intervention (12 weeks) |
| Change in body composition | Assessment of changes in lean mass, fat mass and visceral fat mass (all in grams) using body composition by Dual X-ray Absorptiometry scan | At baseline and at the end of the intervention (12 weeks) |
| Change in skeletal muscle health | muscle strength using handgrip strength tool (kg) | At baseline and at the end of the intervention (12 weeks) |
| Change in skeletal muscle health | Assessment of physical performance using Timed Up and go Test | At baseline and at the end of the intervention (12 weeks) |
| Change in skeletal muscle health | Assessment of functionnal capicity using 6-minute walk test) | At baseline and at the end of the intervention (12 weeks) |
| Change in Resting Metabolic Rate (RMR) | Change in RMR using Calorimetry Device | At baseline and at the end of the intervention (12 weeks) |
| Change in Appetite and Satiety | Assessment of leptin and ghrelin (both with same units of measurement) | At baseline and at the end of the intervention (12 weeks) |
| Change in Appetite and Satiety | Assessment of appetite and satiety using visual analog scale | At baseline and at the end of the intervention (12 weeks) |
| Change in Eating behaviors | Assessment of eating behaviors using Food Cravings Questionnaire (FCQ-T) | At baseline and at the end of the intervention (12 weeks) |
| Change in glycemia | Assessment of fasting glucose concentration | At baseline and at the end of the intervention (12 weeks) |
| Change in insulinemia | Assessment of fasting insulin concentration | At baseline and at the end of the intervention (12 weeks) |
| Change in lipid profile | Assessment of triglycerides, LDL-cholesterol and HDL-cholesterol | At baseline and at the end of the intervention (12 weeks) |
| Change in blood pressure | Assessment of systolic and diastolic blood pressure | At baseline and at the end of the intervention (12 weeks) |
| Change in chronic inflammation | Assessment of plasma high sensitive C-Reactive Protein (hs-CRP) concentrations | At baseline and at the end of the intervention (12 weeks) |
| ID | Term |
|---|---|
| D001836 | Body Weight Changes |
| ID | Term |
|---|---|
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided